HCP, Inc. (NYSE:HCP) Given Consensus Rating of “Buy” by Analysts

Share on StockTwits

HCP, Inc. (NYSE:HCP) has been assigned a consensus recommendation of “Buy” from the sixteen research firms that are presently covering the company, MarketBeat.com reports. Four research analysts have rated the stock with a hold recommendation and eleven have issued a buy recommendation on the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $31.22.

A number of brokerages recently weighed in on HCP. TheStreet upgraded shares of Rent-A-Center from a “c” rating to a “b-” rating in a report on Tuesday, May 7th. KeyCorp cut shares of GTT Communications from an “overweight” rating to a “sector weight” rating in a report on Monday, July 1st. Raymond James began coverage on shares of Adverum Biotechnologies in a report on Thursday, June 13th. They set a “market perform” rating for the company. Finally, Morgan Stanley set a $111.00 target price on shares of Procter & Gamble and gave the stock a “buy” rating in a report on Thursday, March 28th.

In related news, Director Christine Garvey sold 3,405 shares of the company’s stock in a transaction that occurred on Thursday, May 9th. The shares were sold at an average price of $29.80, for a total value of $101,469.00. Following the completion of the sale, the director now owns 5,348 shares in the company, valued at approximately $159,370.40. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 0.13% of the stock is currently owned by corporate insiders.

Several large investors have recently modified their holdings of the stock. BlackRock Inc. lifted its position in shares of HCP by 1.3% in the 1st quarter. BlackRock Inc. now owns 46,737,345 shares of the real estate investment trust’s stock valued at $1,462,881,000 after acquiring an additional 591,173 shares in the last quarter. Barrow Hanley Mewhinney & Strauss LLC lifted its position in HCP by 73.8% in the 4th quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 14,036,864 shares of the real estate investment trust’s stock worth $392,050,000 after buying an additional 5,960,734 shares in the last quarter. JPMorgan Chase & Co. lifted its position in HCP by 5.4% in the 1st quarter. JPMorgan Chase & Co. now owns 11,420,161 shares of the real estate investment trust’s stock worth $357,451,000 after buying an additional 581,291 shares in the last quarter. Deutsche Bank AG lifted its position in HCP by 1,073.7% in the 4th quarter. Deutsche Bank AG now owns 10,704,554 shares of the real estate investment trust’s stock worth $298,971,000 after buying an additional 9,792,507 shares in the last quarter. Finally, Northern Trust Corp lifted its position in HCP by 8.8% in the 1st quarter. Northern Trust Corp now owns 8,540,565 shares of the real estate investment trust’s stock worth $267,320,000 after buying an additional 688,358 shares in the last quarter. Institutional investors and hedge funds own 95.50% of the company’s stock.

Shares of HCP stock traded up $0.05 on Friday, hitting $32.55. The company had a trading volume of 90,182 shares, compared to its average volume of 3,002,070. The business has a 50-day simple moving average of $32.17. The company has a current ratio of 0.80, a quick ratio of 0.80 and a debt-to-equity ratio of 0.90. The stock has a market cap of $15.42 billion, a P/E ratio of 17.91, a PEG ratio of 7.01 and a beta of 0.31. HCP has a 52 week low of $24.47 and a 52 week high of $33.58.

HCP (NYSE:HCP) last issued its earnings results on Wednesday, May 1st. The real estate investment trust reported $0.44 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.43 by $0.01. The firm had revenue of $436.15 million during the quarter, compared to analysts’ expectations of $442.20 million. HCP had a net margin of 59.96% and a return on equity of 18.05%. The firm’s revenue for the quarter was down 9.0% compared to the same quarter last year. During the same period last year, the firm posted $0.48 earnings per share. On average, equities analysts expect that HCP will post 1.74 EPS for the current year.

About HCP

HCP, Inc is a fully integrated real estate investment trust (REIT) that invests in real estate serving the healthcare industry in the United States. HCP owns a large-scale portfolio primarily diversified across life science, medical office and senior housing. Recognized as a global leader in sustainability, HCP has been a publicly-traded company since 1985 and was the first healthcare REIT selected to the S&P 500 index.

Read More: What are defining characteristics of a correction?

Analyst Recommendations for HCP (NYSE:HCP)

Receive News & Ratings for HCP Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HCP and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Newpark Resources  Downgraded to “Sell” at Zacks Investment Research
Newpark Resources Downgraded to “Sell” at Zacks Investment Research
QCR  Downgraded to Sell at BidaskClub
QCR Downgraded to Sell at BidaskClub
Pareteum  Rating Lowered to Hold at BidaskClub
Pareteum Rating Lowered to Hold at BidaskClub
Zacks Investment Research Lowers Melco Resorts & Entertainment  to Hold
Zacks Investment Research Lowers Melco Resorts & Entertainment to Hold
Pintec Technology  & Line  Head-To-Head Analysis
Pintec Technology & Line Head-To-Head Analysis
Avast  Price Target Raised to GBX 350
Avast Price Target Raised to GBX 350


 
© 2006-2019 Zolmax.